Cleveland BioLabs, Inc (CBLI)

Oncology Corporate Profile

Stock Performance

1.5600
0.0000

HQ Location

73 High Street
Buffalo, NY 14203

Company Description

Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. CBL0137 is under development by Incuron, LLC, a joint venture based in the Russian Federation that was founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Cleveland BioLabs, Inc. conducts business in the United States and in the Russian Federation through its wholly and majority owned operating subsidiaries. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia for Medical Research.

Website: http://www.cbiolabs.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
entolimodtoll-like receptor 5 (TLR5)Colorectal cancerI
mobilanoncolytic virusProstate cancerI
entolimodtoll-like receptor 5 (TLR5)Various cancer typesI

View additional information on product candidates here »

Source


http://www.cbiolabs.com

Recent News Headlines

Cleveland BioLabs Reports 2016 Financial Results and Development Progress

2/22/2017 09:01 pm

[Marketwired] - Cleveland BioLabs, Inc. today reported financial results and development progress for the fourth quarter and year ended December 31, 2016.

Cleveland BioLabs Reports Third Quarter 2016 Financial Results and Development Progress

11/14/2016 12:03 pm

[Marketwired] - Cleveland BioLabs, Inc. today reported financial results and development progress for the third quarter ended September 30, 2016.

Cleveland BioLabs Reports Third Quarter 2016 Financial Results and Development Progress

11/14/2016 12:03 pm

[at noodls] - BUFFALO, NY--(Marketwired - Nov 14, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2016. ... This is ...

Cleveland BioLabs Announces a $1.1 Million Cost Realignment With the Department of Defense

10/11/2016 01:00 pm

[at noodls] - BUFFALO, NY--(Marketwired - Oct 11, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Department of Defense (DoD) has modified its Joint Warfighter Medical Research Program (JWMRP) ...

Cleveland BioLabs Announces a $1.1 Million Cost Realignment With the Department of Defense

10/11/2016 12:04 pm

[Marketwired] - Cleveland BioLabs, Inc. today announced that the Department of Defense has modified its Joint Warfighter Medical Research Program contract award number W81XWH-15-C-0101 with CBLI valued at up to $9.2 million ...

Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress

8/15/2016 12:05 pm

[at noodls] - BUFFALO, NY--(Marketwired - Aug 15, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2016. ... This is an abstract ...

Cleveland BioLabs Reports Second Quarter 2016 Financial Results and Development Progress

8/15/2016 12:03 pm

[Marketwired] - Cleveland BioLabs, Inc. today reported financial results and development progress for the second quarter ended June 30, 2016.

Promedica Cancer Institute Launches Affiliation With Cleveland Clinic Cancer Center

8/12/2016 11:33 am

(Cleveland Clinic) Aug 11, 2016 - ProMedica Cancer Institute and Cleveland Clinic Cancer Center have established a formal affiliation to expand access to highly-specialized cancer treatments, clinical expertise and research studies for patients in northwest Ohio and southeast Michigan.